Article thumbnail

Adeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1

By Declan Madsen, Emma R. Cantwell, Timothy O'Brien, Patricia A. Johnson and Bernard P. Mahon

Abstract

Adeno-associated virus serotype 2 (AAV-2) has been developed as a gene therapy vector. Antibody and cell-mediated immune responses to AAV-2 or AAV-2-transfected cells may confound the therapeutic use of such vectors in clinical practice. In one of the most detailed examinations of AAV-2 immunity in humans to date, cell-mediated and humoral immune responses to AAV-2 were characterized from a panel of healthy blood donors. The extent of AAV-2-specific antibody in humans was determined by examination of circulating AAV-2-specific total IgG levels in plasma from 45 normal donors. Forty-one donors were seropositive and responses were dominated by IgG1 and IgG2 subclasses. Conversely, AAV-2-specific IgG3 levels were consistently low in all donors. Cell-mediated immune recall responses were detectable in nearly half the population studied. In vitro restimulation with AAV-2 of peripheral blood mononuclear cell cultures from 16 donors elicited gamma interferon (IFN-γ) (ten donors), interleukin-10 (IL-10) (eight donors) and interleukin-13 (IL-13) (four donors) responses. Using a series of overlapping peptides derived from the sequence of the VP1 viral capsid protein, a total of 59 candidate T-cell epitopes were identified. Human leukocyte antigen characterization of donors revealed that the population studied included diverse haplotypes, but that at least 17 epitopes were recognized by multiple donors and could be regarded as immunodominant. These data indicate that robust immunological memory to AAV-2 is established. The diversity of sequences recognized suggests that attempts to modify the AAV-2 capsid, as a strategy to avoid confounding immunity, will not be feasible

Topics: Animal
Publisher: Society for General Microbiology
OAI identifier: oai:pubmedcentral.nih.gov:2885037
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2003). A novel recombinant adeno-associated virus vaccine reduces behavioural impairment and b-amyloid plaques in a mouse model of Alzheimer’s disease.
  2. (2008). A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs.
  3. (2000). AAV vectors: is clinical success on the horizon?
  4. (2007). Adeno-associated viral vector transduction of human mesenchymal stem cells.
  5. (2005). Adeno-associated viral vectors for clinical gene therapy in the brain.
  6. (1995). Adenovirus and adenoassociated virus mediated gene transfer.
  7. (1965). Adenovirusassociated defective virus particles.
  8. (2000). Building a better vector: the manipulation of AAV virions.
  9. (2004). Clades of adeno-associated viruses are widely disseminated in human tissues.
  10. (2008). Complement is an essential component of the immune response to adeno-associated virus vectors.
  11. (2007). Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets.
  12. (1994). Detection of adeno-associated virus DNA in human genital tissue and in material from spontaneous abortion.
  13. (2006). Determination of specific CD4 and CD8 T cell epitopes after AAV2-and AAV8-hF.IX gene therapy.
  14. (2002). Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors.
  15. (1998). Distinct Th cell subtypes induced with whole cell and acellular pertussis vaccines in children.
  16. (2009). Diverse IgG subclass responses to adeno-associated virus infection and vector administration.
  17. (1968). Epidemiology of adenovirus-associated virus infection in a nursery population.
  18. (1993). Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter.
  19. (1999). Gene therapy vectors based on adeno-associated virus type 1.
  20. (2008). genetically homogenous Irish population.
  21. (1996). IgG subclass response to human parvovirus B19 infection.
  22. Immune responses to AAV and to factor IX in a phase I study of AAV-mediated, liver-directed gene transfer for hemophilia B. Mol Ther 9,
  23. (2005). Immune responses to adenoassociated virus vectors.
  24. (1999). Immune responses to adenovirus and adenoassociated virus in humans.
  25. (1996). Immunoglobulin G subclass antibodies to rubella virus in chronic liver disease, acute rubella and healthy controls.
  26. (2005). Immunoglobulin G subclass profile of antimeasles response in vaccinated children and in adults with measles history.
  27. (2000). Impaired gamma interferon responses against parvovirus B19 by recently infected children.
  28. (2007). Interferon-c does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells.
  29. (1993). Isotypic and IgG subclass restriction of the humoral immune responses to human T-lymphotropic virus type-I.
  30. (1999). Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model.
  31. (1994). Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain.
  32. (2003). Ocular immune privilege: therapeutic opportunities from an experiment of nature.
  33. (2004). other authors
  34. other authors (2004). Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebocontrolled trial.
  35. other authors (2006). Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 a1-antitrypsin (AAT) vector in AAT-deficient adults.
  36. other authors (2006). Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response.
  37. other authors (2007). Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial.
  38. other authors (2007).Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial.
  39. other authors (2008). Treatment of leber congenital amaurosis due to RPE65 mutations by occular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial.
  40. (1997). Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors.
  41. (2007). Pre-existing AAV capsidspecific CD8 + T cells are unable to eliminate AAV-transduced hepatocytes.
  42. (2006). Prevalence of neutralizing Human immunity to AAV-2 http://vir.sgmjournals.org 2631antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: implications for gene therapy using AAV vectors.
  43. (2003). Receptor targeting of adeno-associated virus vectors.
  44. (1997). Recombinant adenoassociated viral vectors mediate long-term transgene expression in muscle.
  45. (2005). Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model.
  46. (2000). Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors.
  47. (1988). Rubella-specific IgG subclass concentrations in sera using an enzyme-linked immunosorbent assay (ELISA): the effect of different sources of rubella antigen.
  48. (1990). Selective IgG subclass deficiency: quantification and clinical relevance.
  49. (1968). Serologic evidence for human infection with adenovirus-associated viruses.
  50. (1990). Site-specific integration by adeno-associated virus.
  51. (1999). SYFPEITHI: database for MHC ligands and peptide motifs.
  52. (2002). The atomic structure of adeno-associated D. Madsen and others 2632 Journal of General Virology 90virus (AAV-2), a vector for human gene therapy.
  53. (2000). The IgG subclass profile of antiHBs response in vaccinated children and children seroconverted after natural infection.
  54. (1970). The role of herpesviruses in adenovirusassociated virus replication in vitro.
  55. (1997). Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence and readministration.
  56. (1999). Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV).
  57. (2003). Vectors for the treatment of autoimmune disease.